TRIPASS XR تري باس

 Cappola AR et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295:1033.

Rodondi N, den Elzen WP, Bauer DC et al. Subclinical hypothyroidism and the risk of coronary heart disease

and mortality. JAMA. 2010;304(12):1365–1374.

Danese MD et al. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a

quantitative review of the literature. J Clin Endocrinol Metab. 2000;85:2993.

Wardle CA et al. Pitfalls in the use of thyrotropin concentration as a first-line thyroid function test. Lancet.

2001;357:1013.

Pollock MA et al. Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests

within the reference range: randomised double-blind placebo-controlled crossover trial. Br Med J. 2001;323:891.

Weetman AP. Thyroxine treatment in biochemically euthyroid but clinically hypothyroid individuals. Clin

Endocrinol. 2002;57:25.

Brent GA. Clinical practice: Graves’ disease. N EnglJ Med. 2008;358:2594–2605

Shimizu T et al. Hyperthyroidism and the management of atrial f ibrillation. Thyroid. 2002;12:489.

Loeliger EA et al. The biological disappearance rate of prothrombin factors VII, IX, X from plasma in hypo-,

hyper-, and during fever. Thromb Diath Haemorrh. 1964;10:267.

Lipsky JJ, Gallego MO. Mechanism of thioamide antithyroid drug-associated hypoprothrombinemia. Drug Metab

Drug Interact. 1988;6:317.

Liaw Y et al. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism: a cohort study. Ann

Intern Med. 1993;118:424.

Hardee JT et al. Propylthiouracil-induced hepatotoxicity. West J Med. 1996;165(3):144–147.

Williams KV et al. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we

learned? J Clin Endocrinol Metab. 1997;82:1727.

Woeber KA. Methimazole-induced hepatotoxicity. Endocr Pract. 2002;8:222.

Frye RL, Braunwald E. Studies on digitalis III: the influence of triiodothyronine on digitalis requirement.

Circulation. 1961;23:376.

Burgi H. Iodine excess. Best Pract Res Clin Endocrinol Metab. 2010;24:107–117.

Arbelle JE, Porath A. Practice guidelines for the detection and management of thyroid dysfunction: a

comparative review of the recommendations. Clin Endocrinol. 1999;51:11.

Abraham P et al. Antithyroid drug regimen for treating Graves’ hyperthyroidism [review]. Cochrane Database

Syst Rev. 2005:CD003420.

Cooper DS. Antithyroid drugs. N EnglJ Med. 2005;352:905.

Jongjaroenprasert W et al. Rectal administration of propylthiouracil in hyperthyroid patients: comparison of

suspension enema and suppository form. Thyroid. 2002;12:627.

Yeung SCJ et al. Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm. Thyroid.

1995;5:403.

Nabil N et al. Methimazole: an alternative route of administration. J Clin Endocrinol Metab. 1982;54:180.

Alsanea O, Clark OH. Treatment of Graves’ disease: the advantages of surgery. Endocrinol Metab Clin North

Am. 2000;29:321.

Torring O et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine: a prospective,

randomized study. J Clin Endocrinol Metab. 1996;81:2986.

Boostrom S, Richards ML. Total thyroidectomy is the preferred treatment for patients with Graves’ disease and

a thyroid nodule. Otolaryngol Head Neck Surg. 2007;136:278.

Palit TK et al. The efficacy of thyroidectomy for Graves’ disease: a meta-analysis. J Surg Res. 2000;90:161.

184.

185.

186.

187.

188.

189.

190.

191.

192.

193.

194.

195.

196.

197.

198.

199.

200.

201.

202.

203.

204.

205.

206.

207.

208.

209.

210.

211.

Ross DS. Radioiodine therapy for hyperthyroidism. N EnglJ Med. 2011;364:542.

Ron E et al. Cancer mortality following treatment for adult hyperthyroidism: Cooperative Thyrotoxicosis Therapy

Follow-up Study Group. JAMA. 1998;280:347.

Rivkees SA. The management of hyperthyroidism in children with emphasis on the use of radioactive iodine.

Pediatr Endocrinol Rev. 2003;1(Suppl 2):212.

Read CH et al. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating

young Graves’ patients. J Clin Endocrinol Metab. 2004;89:4229.

Robertson J, Gorman CA. Gonadal radiation dose and its genetic significance in radioiodine therapy of

hyperthyroidism. J Nucl Med. 1976;17:826.

Holm LE. Thyroid cancer after exposure to radioactive 131I. Acta Oncol. 2006;45:1037.

Zuckier L et al. Sensitivity of personal Homeland Security radiation detectors to medical radionuclides and

implications for counseling of nuclear medicine patients. In: Presented as part of SSJ19: Physics (Nuclear

Medicine, PET, MR Imaging), Chicago, IL; 2004.

Gangopadhyay KK et al. Patients treated with radioiodine can trigger airport radiation sensors for many weeks.

BMJ. 2006;333:293.

Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am. 2006;35:663.

Cooper DS et al. Methimazole pharmacology in man: studies using a newly developed radioimmunoassay for

methimazole. J Clin Endocrinol Metab. 1984;58:473.

McIver B, Morris JC. The pathogenesis of Graves’ disease. Endocrinol Metab Clin North Am. 1998;27:73.

Allannic H et al. Antithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of

treatment duration. J Clin Endocrinol Metab. 1990;70:675.

Maugendre D et al. Antithyroid drugs and Graves’ disease: prospective randomized assessment of long-term

treatment. Clin Endocrinol. 1999;50:127.

Bolanos F et al. Remission of Graves’ hyperthyroidism treated with methimazole. Rev Invest Clin. 2002;54:307.

Nijs HG et al. Increased insulin action and clearance in hyperthyroid newly diagnosed IDDM patient: restoration

to normal with antithyroid treatment. Diabetes Care. 1989;12:319.

Aloush V et al. Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different

course and management. Semin Arthritis Rheum. 2006;36:4.

Geffner DL, Hershman JM. Beta-adrenergic blockade for the treatment of hyperthyroidism. Am J Med.

1992;93:61.

Milner MR et al. Double-blind crossover trial of diltiazem versus propranolol in the management of thyrotoxic

symptoms. Pharmacotherapy. 1990;10:100.

Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med.

2009;360(15):1574–1575.

Bahn RS et al. The Role of Propylthiouracil in the management of Graves’ disease in adults: report of a meeting

jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid.

2009;19(7):673–674.

Tajiri J et al. Antithyroid drug-induced agranulocytosis: the usefulness of routine white blood cell count

monitoring. Arch Intern Med. 1990;150:621.

Wall JR et al. In vitro immunosensitivity to propylthiouracil, methimazole, and carbimazole in patients with

Graves’ disease: a possible cause of antithyroid drug-induced agranulocytosis. J Clin Endocrinol Metab.

1984;58:868.

Jakucs J, Pocsay G. Successful treatment of methimazole-induced severe aplastic anemia with recombinant

human granulocyte colony-stimulating factor and high-dosage steroids. J Endocrinol Invest. 2006;29:74.

Gaujoux et al. Extensive thyroidectomy in Graves’ disease. J Am Coll Surg. 2006;202:868.

Orgiazzi J, Madec AM. Reduction of the risk of relapse after withdrawal of medical therapy for Graves’

disease. Thyroid. 2002;12:849.

Vitti P et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug

treatment. Thyroid. 1997;3:369.

Glinoer D et al. Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of

recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized

study. Eur J Endocrinol. 2001;144:475.

Hashizume K et al. Administration of thyroxine in treated Graves’ disease: effects on the level of antibodies to

thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med.

1991;324:947.

212.

213.

214.

215.

216.

217.

218.

219.

220.

221.

222.

223.

224.

225.

226.

227.

228.

229.

230.

231.

232.

233.

234.

235.

236.

237.

238.

239.

240.

241.

Vestergaard P. Smoking and thyroid disorders—a meta-analysis. Eur J Endocrinol. 2002;146:153.

Hoermann R et al. Relapse of Graves’ disease after successful outcome of antithyroid drug therapy: results of a

prospective randomized study on the use of levothyroxine. Thyroid. 2002;12:1119.

McIver B et al. Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an

antithyroid drug. N EnglJ Med. 1996;334:220.

Sawin CT et al. Low serum thyrotropin concentrations as a risk factor for atrial f ibrillation in older patients. N

EnglJ Med. 1994;331:1249.

Vadiveloo T et al. The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of

endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab. 2011;96(1):E1–E8.

Mestman JH. Hyperthyroidism in pregnancy. Best Pract Res Clin Endocrinol Metab. 2004;18:267.

Atkins P et al. Drug therapy for hyperthyroidism in pregnancy:safety issues for mother and fetus. Drug Safety.

2000;23:229.

Bulletin AP. Thyroid disease in pregnancy. Obstet Gynecol. 2002;100:387.

Fitzpatrick DL, Russell MA. Diagnosis and management of thyroid disease in pregnancy. Obstet Gynecol Clin

North Am. 2010;37(2):173–193.

Wing DA et al. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in

pregnancy. Am J Obstet Gynecol. 1994;170:90.

Mortimer RH et al. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J

Clin Endocrinol Metab. 1997;82:3099.

Momotani N et al. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves’

hyperthyroidism. J Clin Endocrinol Metab. 1997;82:3633.

Momotani N et al. Maternal hyperthyroidism and congenital malformation in the offspring. Clin Endocrinol.

1984;20:695.

Van Dijke CP et al. Methimazole, carbimazole, and congenital skin defects [letter]. Ann Intern Med.

1987;106:60.

Momotani N et al. Antithyroid drug therapy for Graves’ disease during pregnancy: optimal regimen for fetal

thyroid status. N EnglJ Med. 1986;315:24.

Wolf D et al. Antenatal carbimazole and choanal atresia: a new embryopathy. Arch Otolaryngol Head Neck

Surg. 2006;132:1009.

Eisenstein Z et al. Intellectual capacity of subjects exposed to methimazole or propylthiouracil in utero. Eur J

Pediatr. 1992;151:558.

Burrow GN et al. Intellectual development in children whose mothers received propylthiouracil during

pregnancy. Yale J Biol Med. 1978;51:151.

Messer MP et al. Antithyroid drug and Graves’ disease in pregnancy: long-term effects on somatic growth,

intellectual development and thyroid function of the offspring. Acta Endocrinol. 1990;123:311.

Momotani N et al. Thyroid function in wholly breast-feeding infants whose mothers take high doses of

propylthiouracil. Clin Endocrinol. 2000;53:177.

Azizi F et al. Thyroid function and intellectual development of infants nursed by mothers taking methimazole. J

Clin Endocrinol Metab. 2000;85:3233.

Iagaru A, McDougall IR. Treatment of thyrotoxicosis. J Nucl Med. 2007;48:379.

Kubota S, Ohye H, Yano G, al. E. Two-day thionamide withdrawal prior to radioiodine uptake sufficiently

increases uptake and does not exacerbate hyperthyroidism compared to 7 day withdrawal in Graves’ disease.

Endocr J. 2006;53:603–607.

Imseis RE et al. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of

iodine-131 in hyperthyroidism. J Clin Endocrinol Metab. 1998;83:685.

Braga M et al. The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism:

a randomized clinical trial. Thyroid. 2002;12:135.

Bartalena L et al. Management of Graves’ ophthalmopathy: reality and perspectives. Endocrinol Rev.

2000;21:168.

Wiersinga WM. Management of Graves’ ophthalmopathy. Nat Clin Pract Endocrinol Metab. 2007;3:396.

Bahn RS. Graves’ ophthalmopathy. N EnglJ Med. 2010;362(8):726–738.

Bartalena L et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N

EnglJ Med. 1998;338:73.

Dorkhan M et al. Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type

2 diabetes. Clin Endocrinol (Oxf). 2006;65:35.

242.

243.

244.

245.

246.

247.

248.

249.

250.

251.

252.

253.

254.

255.

256.

Marcocci C et al. Relationship between Graves’ ophthalmopathy and type of treatment of Graves’

hyperthyroidism. Thyroid. 1992;2:171.

Lai A et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent

graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab. 2010;95(3):1333–1337.

Tsai WC et al. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of

Graves’ hyperthyroidism. Clin Endocrinol. 2005;62:521.

McCowen KC et al. Elevated serum thyrotropin in thyroxine treated patients with hypothyroidism given

sertraline [letter]. N EnglJ Med. 1997;337:1010.

Bogazzi F et al. Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodaroneinduced thyrotoxicosis before thyroidectomy. Surgery. 2002;132:1114.

Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated

thyroid cancer. Thyroid. 2010;20(2):135–146.

Basaria M et al. The use of recombinant thyrotropin in the follow-up of patients with differentiated thyroid

cancer. Am J Med. 2002;112:721.

Fontanilla JC et al. The use of oral radiographic contrast agents in the management of hyperthyroidism. Thyroid.

2001;22:561.

Wu SY et al. Comparison of sodium ipodate (Oragrafin) and propylthiouracil in early treatment of

hyperthyroidism. J Clin Endocrinol Metab. 1982;54:630.

Bal CS et al. Effect of iopanoic acid on radioiodine therapy of hyperthyroidism: long-term outcome of a

randomized controlled trial. J Clin Endocrinol Metab. 2005;90:6536.

Roti E et al. Sodium ipodate and methimazole in the long-term treatment of hyperthyroid Graves’ disease.

Metabolism. 1993;42:403.

Martino E et al. Therapy of Graves’ disease with sodium ipodate is associated with a high recurrence rate of

hyperthyroidism. J Endocrinol Invest. 1991;14:847.

Fliers E et al. The hypothalamic-pituitary-thyroid axis in critical illness. Best Pract Res Clin Endocrinol Metab.

2001;15:453.

Lee E et al. Effect of acute high-dose dobutamine administration on serum thyrotropin (TSH). Clin Endocrinol.

1999;50:486.

Keogh MA, Wittert GA. Effect of cabergoline on thyroid function in hyperprolactinaemia [letter]. Clin

Endocrinol. 2002;57:699.

p. 1070

A glycosylated hemoglobin (A1C) level can be used to diagnose

diabetes, in addition to a fasting plasma glucose (FPG) or oral glucose

tolerance test (OGTT). Each test must be confirmed on a subsequent

day.

Case 53-2 (Question 1),

Case 53-11 (Question 1)

The primary metabolic goals for diabetes are an A1C less than 7%, a

systolic blood pressure less than 140 mm Hg, and statin therapy for

most patients over the age of 40. Management of cholesterolshould

include a statin drug, and management of hypertension should include an

angiotensin-converting enzyme inhibitor or angiotensin II receptor

blocker.

Case 53-2 (Question 2),

Case 53-11 (Question 2)

Glycemic treatment goals should be individualized. For patients with a

short duration of diabetes, long life expectancy, and no significant

vascular disease, more stringent goals can be considered, if it can be

achieved without increasing hypoglycemia. For patients with existing

vascular disease, other significant macrovascular or microvascular

disease, a history of hypoglycemia, or limited life expectancy, or for

those with long-standing diabetes who have difficulty lowering their

A1C, a less stringent A1C goalshould be considered.

Case 53-2 (Question 2),

Case 53-4 (Question 2),

Case 53-11 (Question 2),

Case 53-18 (Question 3)

Medical nutrition therapy (MNT) and physical activity are cornerstones

to the treatment of diabetes.

Case 53-2 (Questions 11,

12), Case 53-11 (Question

3),

Case 53-18 (Question 4)

Self-monitoring of blood glucose (SMBG) should be performed by all

patients with Type 1 diabetes and most patients with Type 2 diabetes,

particularly those on antidiabetic therapy that can cause hypoglycemia

or those engaged in self-management. The key to SMBG is to educate

patients on how to respond to their blood glucose (BG) levels.

Case 53-2 (Questions 9–11),

Case 53-4 (Question 5),

Case 53-11 (Question 6)

Basal-bolus insulin regimens should be used for patients with Type 1

diabetes. These can be administered either by multiple daily injections or

by an insulin pump. Basal-bolus insulin regimens are also effective for

patients with Type 2 diabetes who no longer are able to achieve A1C

goals with noninsulin therapies.

Case 53-2 (Questions 3–6),

Case 53-4 (Question 3),

Case 53-13 (Question 6)

Metformin is the first-line therapy for Type 2 diabetes unless a patient Case 53-11 (Questions 3–5)

has a contraindication to its use or is unable to tolerate this agent. It

should be added at diagnosis along with lifestyle changes.

After monotherapy, a second antidiabetic agent should be added to the

regimen. Factors to consider include the patient’s A1C goal, the amount

of reduction in A1C required, the patient’s kidney and liver function,

medication side effects, and cost of therapy.

Case 53-11 (Question 7),

Case 53-12 (Question 1),

Case 53-13 (Questions 2–4)

InType 2 diabetes, insulin therapy should be considered any time the

patient’s A1C is severely uncontrolled (e.g., A1C >10%) and also when

the A1C is more than 8.5% to 9%, and a patient is already on

combination oral therapy. It should be considered whether a patient is

symptomatic.

Case 53-11 (Question 7),

Case 53-12 (Question 1),

Case 53-13 (Question 5)

p. 1071

p. 1072